Merck (MRK) has a done a lot right in cancer immunotherapy, probably more than any of its pharma rivals. But the clinical debut of a new immune-boosting drug from its early-stage cancer pipeline Saturday suggests Merck is not heeding a hard lesson learned from its biggest blunder.
The new Merck drug, called MK-1454, shows no evidence that it can kill cancer cells when injected into patients on its own, as a monotherapy. But when MK-1454 was used in combination with Merck’s checkpoint inhibitor Keytruda, the tumors in a small number of patients got smaller.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
